Prophylactic use of ondansetron for emesis after craniofacial operations in children.

Abstract

Children who undergo craniofacial operations are especially at risk of postoperative nausea and vomiting. These operations are more complex than the craniotomies for resective procedures. Postoperative vomiting is a common occurrence that can delay recovery and result in cerebrospinal fluid leak and fistula formation in these patients. Ondansetron, a selective serotonergic antagonist, is effective in reducing postoperative nausea and vomiting in several high-risk populations. In a randomized, double-blind, placebo-controlled study, the authors compared the prophylactic use of intravenous ondansetron 0.15 mg/kg with induction of anesthesia versus a placebo of normal saline 0.3 ml/kg with induction. A second dose was given 8 hours after the first dose. After surgery, episodes of vomiting were recorded separately in 0 to 2 hours, 2 to 6 hours, 6 to 12 hours, 12 to 24 hours, and 24 to 48 hours. Postoperative vomiting is significantly reduced in the ondansetron group compared with the placebo group (P = 0.000258). Ondansetron is effective in the prevention of postoperative vomiting in the pediatric population undergoing craniofacial operations.

• Authors: T Gürler, N Celik, S Totan, E Songür, M Sakarya
• Journal: The Journal of craniofacial surgery (J Craniofac Surg) Vol. 10 Issue 1 Pg. 45-8 (Jan 1999) ISSN: 1049-2275 [Print] United States
• PMID: 10388426 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Antiemetics
• Ondansetron

Topics

• Antiemetics (therapeutic use)
• Child
• Craniofacial Abnormalities (surgery)
• Craniotomy (adverse effects)
• Double-Blind Method
• Humans
• Ondansetron (therapeutic use)
• Postoperative Nausea and Vomiting (etiology, prevention & control)